Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
07 03 2023
Historique:
entrez: 28 2 2023
pubmed: 1 3 2023
medline: 3 3 2023
Statut: ppublish

Résumé

Engagement of the inhibitory T cell receptor programmed cell death protein 1 (PD-1) associates with dysfunctional states of pathogen- or tumor-specific T cells. Accordingly, systemic antibody-mediated blockade of PD-1 has become a central target for immunotherapies but is also associated with severe toxicities due to loss of peripheral tolerance. Therefore, selective ablation of PD-1 expression on adoptively transferred T cells through direct genetic knockout (KO) is currently being explored as an alternative therapeutic approach. However, since PD-1 might also be required for the regulation of physiological T cell function and differentiation, the suitability of PD-1 as an engineering target is controversial. In this study, we systematically investigated the maintenance of T cell functionality after CRISPR/Cas9-mediated PD-1 KO in vivo during and after acute and chronic antigen encounter. Under all tested conditions, PD-1 ablation preserved the persistence, differentiation, and memory formation of adoptively transferred receptor transgenic T cells. Functional PD-1 KO T cells expressing chimeric antigen receptors (CARs) targeting CD19 could be robustly detected for over 390 d in a syngeneic immunocompetent mouse model, in which constant antigen exposure was provided by continuous B cell renewal, representing the longest in vivo follow-up of CAR-T cells described to date. PD-1 KO CAR-T cells showed no evidence for malignant transformation during the entire observation period. Our data demonstrate that genetic ablation of PD-1 does not impair functionality and longevity of adoptively transferred T cells per se and therefore may be pursued more generally in engineered T cell-based immunotherapy to overcome a central immunosuppressive axis.

Identifiants

pubmed: 36853939
doi: 10.1073/pnas.2200626120
pmc: PMC10013756
doi:

Substances chimiques

Programmed Cell Death 1 Receptor 0
Adaptor Proteins, Signal Transducing 0
Antibodies, Blocking 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2200626120

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB 1321/1—329628492 (PROJECT P17)
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB-TRR 338/1 2021—452881907 (PROJECT A01)
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2830 (PROJECT 5)

Références

Oncotarget. 2017 Dec 27;9(4):5208-5215
pubmed: 29435173
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
Sci Immunol. 2021 Jan 15;6(55):
pubmed: 33452106
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
Elife. 2020 Mar 31;9:
pubmed: 32228854
Nat Med. 2017 Feb;23(2):242-249
pubmed: 28067900
Biomed Pharmacother. 2020 Jan;121:109625
pubmed: 31733578
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Immunity. 2020 Nov 17;53(5):985-1000.e11
pubmed: 33128876
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Cancer Immunol Immunother. 2019 Oct;68(10):1701-1712
pubmed: 31542797
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Immunol. 2011 Jun 1;186(11):6280-6
pubmed: 21525385
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
J Exp Med. 2015 Jun 29;212(7):1125-37
pubmed: 26034050
J Virol. 2006 Nov;80(22):11398-403
pubmed: 16956940
Nat Biomed Eng. 2019 Dec;3(12):974-984
pubmed: 31182835
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
J Clin Invest. 2006 Jun;116(6):1675-85
pubmed: 16710479
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Mol Med Rep. 2018 Feb;17(2):2083-2088
pubmed: 29207115
Nat Commun. 2019 Sep 11;10(1):4109
pubmed: 31511513
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Nat Immunol. 2020 Dec;21(12):1563-1573
pubmed: 33106669
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
Sci Transl Med. 2021 Oct 13;13(615):eaba6006
pubmed: 34644150
Nature. 2017 Dec 7;552(7683):121-125
pubmed: 29143824
Ann N Y Acad Sci. 2011 Jan;1217:45-59
pubmed: 21276005
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Cell Rep. 2020 Jun 30;31(13):107827
pubmed: 32610128
PLoS One. 2013 Apr 09;8(4):e61338
pubmed: 23585892
Oncotarget. 2016 Nov 22;7(47):76902-76919
pubmed: 27708227
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Clin Invest. 2016 Nov 1;126(11):4262-4272
pubmed: 27760047
Trends Microbiol. 2018 Jun;26(6):498-509
pubmed: 29249600
Cancer Immunol Immunother. 2019 Mar;68(3):365-377
pubmed: 30523370
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Immunity. 2014 Jul 17;41(1):116-26
pubmed: 25035956
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8623-8
pubmed: 19433785
J Immunother Cancer. 2019 Nov 14;7(1):304
pubmed: 31727131
PLoS One. 2013;8(2):e56539
pubmed: 23409193
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
Cell Res. 2017 Jan;27(1):154-157
pubmed: 27910851
Front Pharmacol. 2018 Oct 01;9:1118
pubmed: 30327605

Auteurs

Sarah Dötsch (S)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Mortimer Svec (M)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Kilian Schober (K)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.
Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Medical Immunology Campus Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossplatz 1, 91054 Erlangen, Germany.

Monika Hammel (M)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Andreas Wanisch (A)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Füsun Gökmen (F)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Sebastian Jarosch (S)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Linda Warmuth (L)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Jack Barton (J)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Luka Cicin-Sain (L)

Department of Viral Immunology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
Centre for Individualized Infection Medicine, a joint venture of Helmholtz Centre for Infection Research and Medical School Hannover, 38624 Hannover, Germany.

Elvira D'Ippolito (E)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.

Dirk H Busch (DH)

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.
German Center for Infection Research, Deutschen Zentrum für Infektionsforschung (DZIF), Partner Site Munich, 81675 Munich, Germany.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH